Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16962402 | 0.94 | FFAR4 (0.44) | FFAR4NOS3NOS1NOS2HTT | |
| SCHEMBL5568680 | 0.90 | FFAR4 (0.40) | FFAR4NOS3NOS1NOS2HTT | |
| SCHEMBL7737459 | 0.88 | ALDH1A1 (0.55) | FFAR4NOS3NOS1NOS2HTT | |
| SCHEMBL11802721 | 0.87 | FFAR4 (0.41) | FFAR4NOS3NOS1NOS2HTT | |
| SCHEMBL16951358 | 0.85 | NPC1 (0.54) | FFAR4NOS3NOS1NOS2HTT | |
| SCHEMBL3690305 | 0.84 | ALDH1A1 (0.44) | CNR1ALDH1A1TSHRPGK1PGK2 | |
| SCHEMBL11793154 | 0.83 | HPGD (0.58) | NOS2HTTNPC1HPGDMAPK1 | |
| SCHEMBL16955117 | 0.83 | TACR1 (0.39) | FFAR4NOS3NOS1NOS2HTT | |
| SCHEMBL13952228 | 0.83 | FFAR4 (0.39) | FFAR4NOS3NOS1NOS2HTT | |
| SCHEMBL16956257 | 0.83 | PGK1 (0.39) | FFAR4NOS3NOS1NOS2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915998-B1 | APPLICATION OF SALIDROSIDE DERIVATIVE IN SKIN-WHITENING AGENT FOR EXTERNAL USE | SHANGHAI CHEERMORE BIOLOGICAL TECH CO LTD (CN) | 2023-01-18 | — | — | EP | disclosed |
| CN-110225820-B | Method for manufacturing polymer film laminated substrate and flexible electronic device | 东洋纺株式会社 | 2022-01-28 | — | — | CN | disclosed |
| CN-107698437-A | A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons | 朱翠英 | 2018-02-16 | — | — | CN | disclosed |
| CN-107698436-A | Method for preparing aromatic polycarboxylic acid derivative | 朱翠英 | 2018-02-16 | — | — | CN | disclosed |
| CN-107698445-A | A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons | 朱翠英 | 2018-02-16 | — | — | CN | disclosed |
| CN-107698438-A | A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons | 朱翠英 | 2018-02-16 | — | — | CN | disclosed |
| EP-2683697-B1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-103947031-B | Organic electrolyte and organic electrolyte secondary battery | 吉坤日矿日石能源株式会社 | 2017-07-11 | — | — | CN | disclosed |
| CN-104025364-B | Organic bath and organic bath accumulator | 吉坤日矿日石能源株式会社 | 2017-03-08 | — | — | CN | disclosed |
| US-9145522-B2 | Enhanced aromatics production by low pressure end point reduction and selective hydrogenation and hydrodealkylation | UOP LLC (US) | 2015-09-29 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| EP-0233450-B1 | LINEAR SALICYLIC ACID COPOLYMERS AND THEIR METAL SALTS, PRODUCTION PROCESS THEREOF, COLOR-DEVELOPING AGENTS COMPRISING METAL-RESINS OF THE COPOLYMERS, AND COLOR-DEVELOPING SHEETS EMPLOYING THE AGENTS | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4783521-A | Linear salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal-resins of the copolymers | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0233450-A2 | Linear salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal-resins of the copolymers, and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-08-26 | — | — | EP | disclosed |
| US-4300007-A | Method for preparing C3 -C4 olefins and vinylaromatic compounds | POLYAKOV SERGEI A | 1981-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | FFAR4 1761/4885NOS3 3411/4885NOS1 3501/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | FFAR4 440/4885NOS3 3675/4885NOS1 4155/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | FFAR4 3854/4885NOS3 3808/4885NOS1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.